Enzolytics Inc (ENZC)

[Wisdom of Locke]

"Securities Exchange Agreements

On November 16, 2020, the Company entered into Securities Exchange Agreements with two investors. Under the terms of the Securities Exchange Agreements, the Company issued 941,078 shares of its Series Convertible Preferred Stock and 188,215,600 warrants to purchase 188,215,600 shares of its common stock in exchange for payment of various notes and accrued interest totaling $470,539 to these investors. Each share of the Series C Convertible Preferred Stock is convertible at price of $0.005 anytime at the option of the investors"

(sigh). Like I said, old news.

Obviously not everyone reads disclosures. The 12/31/2020 disclosure lists each individual that was issued shares as part of the BioClonetics transaction. All shares issued after that had to be listed in the disclosures. The issuance of the Series E was in the 9/30/2021 disclosure statement and the Series D are associated with the crowdfunding debt assumed from BioClonetics. All stock designations are filed with the Secretary of State and can be viewed there.